Allgens Medical Technology CO., LTD. (SHA:688613)
China
· Delayed Price · Currency is CNY 23.20
+0.91 (4.08%)
Mar 10, 2026, 3:00 PM CST
SHA:688613 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 223.51 | 200.43 | 218.43 | 240.28 | 234.15 | Upgrade
|
| Other Revenue | - | 5.6 | 8.05 | 5.02 | 1.91 | Upgrade
|
| Revenue | 223.51 | 206.03 | 226.48 | 245.31 | 236.06 | Upgrade
|
| Revenue Growth (YoY) | 8.48% | -9.03% | -7.68% | 3.91% | 28.46% | Upgrade
|
| Cost of Revenue | - | 59.4 | 39.24 | 40.79 | 35.62 | Upgrade
|
| Gross Profit | 223.51 | 146.63 | 187.24 | 204.51 | 200.44 | Upgrade
|
| Selling, General & Admin | - | 123.6 | 122.04 | 69.95 | 53.35 | Upgrade
|
| Research & Development | - | 38.77 | 45.5 | 57.46 | 33.23 | Upgrade
|
| Other Operating Expenses | 210.9 | 3.57 | 2.58 | 2.58 | 3.09 | Upgrade
|
| Operating Expenses | 210.9 | 174.08 | 171.22 | 130.6 | 90.16 | Upgrade
|
| Operating Income | 12.6 | -27.44 | 16.02 | 73.91 | 110.28 | Upgrade
|
| Interest Expense | - | -2.95 | -3.13 | -1.87 | -3.42 | Upgrade
|
| Interest & Investment Income | - | 15.06 | 6.18 | 5.62 | 4.28 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 0.53 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.13 | 0 | 0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.29 | -1.13 | -0.34 | 0.05 | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | 12.89 | -16.59 | 18.73 | 77.72 | 111.61 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 6.35 | 15.1 | 10.2 | 14.39 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.64 | -0.59 | -0.32 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -0.01 | Upgrade
|
| Other Unusual Items | - | 0.66 | 15.85 | 8.61 | 6.07 | Upgrade
|
| Pretax Income | 12.89 | -8.94 | 49.09 | 96.2 | 132.05 | Upgrade
|
| Income Tax Expense | -0.26 | 8.2 | -3.87 | 4.5 | 13.98 | Upgrade
|
| Earnings From Continuing Operations | 13.15 | -17.14 | 52.97 | 91.7 | 118.07 | Upgrade
|
| Minority Interest in Earnings | - | 4.48 | 1.27 | 3.52 | 2.71 | Upgrade
|
| Net Income | 13.15 | -12.66 | 54.23 | 95.22 | 120.78 | Upgrade
|
| Net Income to Common | 13.15 | -12.66 | 54.23 | 95.22 | 120.78 | Upgrade
|
| Net Income Growth | - | - | -43.04% | -21.17% | 35.80% | Upgrade
|
| Shares Outstanding (Basic) | 132 | 141 | 132 | 134 | 120 | Upgrade
|
| Shares Outstanding (Diluted) | 132 | 141 | 132 | 134 | 120 | Upgrade
|
| Shares Change (YoY) | -6.53% | 6.36% | -1.37% | 12.14% | 19.66% | Upgrade
|
| EPS (Basic) | 0.10 | -0.09 | 0.41 | 0.71 | 1.01 | Upgrade
|
| EPS (Diluted) | 0.10 | -0.09 | 0.41 | 0.71 | 1.01 | Upgrade
|
| EPS Growth | - | - | -42.25% | -29.70% | 13.48% | Upgrade
|
| Free Cash Flow | - | -33.03 | 29.78 | 56.63 | 68.54 | Upgrade
|
| Free Cash Flow Per Share | - | -0.23 | 0.23 | 0.42 | 0.57 | Upgrade
|
| Dividend Per Share | - | - | 0.060 | 0.107 | 0.272 | Upgrade
|
| Dividend Growth | - | - | -43.92% | -60.66% | - | Upgrade
|
| Gross Margin | 100.00% | 71.17% | 82.67% | 83.37% | 84.91% | Upgrade
|
| Operating Margin | 5.64% | -13.32% | 7.07% | 30.13% | 46.72% | Upgrade
|
| Profit Margin | 5.88% | -6.15% | 23.95% | 38.82% | 51.17% | Upgrade
|
| Free Cash Flow Margin | - | -16.03% | 13.15% | 23.09% | 29.04% | Upgrade
|
| EBITDA | 29.62 | -10.43 | 30.81 | 88.11 | 121.03 | Upgrade
|
| EBITDA Margin | 13.25% | -5.06% | 13.61% | 35.92% | 51.27% | Upgrade
|
| D&A For EBITDA | 17.02 | 17.02 | 14.79 | 14.2 | 10.75 | Upgrade
|
| EBIT | 12.6 | -27.44 | 16.02 | 73.91 | 110.28 | Upgrade
|
| EBIT Margin | 5.64% | -13.32% | 7.07% | 30.13% | 46.72% | Upgrade
|
| Effective Tax Rate | - | - | - | 4.68% | 10.59% | Upgrade
|
| Revenue as Reported | - | 206.03 | 226.48 | 245.31 | 236.06 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.